Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administra...
保存先:
主要な著者: | , , |
---|---|
フォーマット: | 図書 |
出版事項: |
Frontiers Media S.A.,
2024-02-01T00:00:00Z.
|
主題: | |
オンライン・アクセス: | Connect to this object online. |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
請求記号: |
A1234.567 |
---|---|
所蔵 1 | 利用可 |